| Similar Articles |
|---|
 |
The Motley Fool
September 28, 2006
Jack Uldrich |
Is CuraGen Hiding a Genomic Gem? A majority ownership stake in 454 Life Sciences could pay hefty dividends.   |
Bio-IT World
Jul/Aug 2006
Kate McDonald |
The Next Generation in Sequencing Is SOLiD Applied Biosystems has completed the acquisition of genetic analysis company Agencourt Personal Genomics for $120 million, and hopes to bring the company's novel next-generation sequencing technology to market next year. |
The Motley Fool
August 12, 2009
Brian Orelli |
The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing. |
Chemistry World
April 19, 2013
Sarah Houlton |
Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis. |
The Motley Fool
January 14, 2010
Brian Orelli |
$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome. |
Bio-IT World
September 2005
Kevin Davies |
Fantastic 454: DNA Sequencing Pyrotechnics In an exciting advance for DNA sequencing technology, a research team at 454 Life Sciences Corp. has essentially sequenced and assembled a bacterial genome sequence based on a mere 4-hour run on the company's proprietary instrument. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
Bio-IT World
November 14, 2003
Julia Boguslavsky |
Genome Center in a Box Scientists at 454 Life Sciences developed an integrated end-to-end instrument that performs hundreds of thousands of reactions in parallel -- from sample preparation, amplification, and sequencing to data storage and bioinformatics. |
Chemistry World
August 22, 2014
Phillip Broadwith |
Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. |
Bio-IT World
April 2007 |
News Briefs Molecular Medicine's "Best of Show"... Dissolving Assets... Combined Forces... |
Chemistry World
May 29, 2014
Hepeng Jia |
Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market. |
The Motley Fool
August 18, 2010
Luke Timmerman |
Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing. |
The Motley Fool
January 3, 2012
Alex Planes |
Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on. |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
Chemistry World
April 3, 2008
Lewis Brindley |
DNA Read in a Trice The prospect of treatments that are tailored to fit an individual's genetic makeup is a step closer thanks to technology unveiled by US scientists. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
The Motley Fool
May 28, 2010
Brian Orelli |
Is It Time to Make Money Investing in Genetic Testing? Easier said than done. |
Bio-IT World
April 2006
Karen Hopkin |
AGBT Meeting Puts Genome Advances Front and Center If the presentations at February's Advances in Genome Biology and Technology (AGBT) are any indication, the race to generate fresh approaches to produce more sequence for less is far from over -- and looks to be heating up. |
The Motley Fool
December 31, 2010
Brian Orelli |
3 Biotech 2010 IPOs Worthy of a Look These IPOs are worth a spot on your watchlist. |
The Motley Fool
December 30, 2008
Brian Orelli |
A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership. |
The Motley Fool
October 28, 2009
Brian Orelli |
Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably. |
Bio-IT World
June 2005
Maureen McDonough |
Celera Releases Genome Data In a decision that essentially marks the end of the genome wars, Celera Genomics will release its formerly proprietary human, mouse, and rat genome sequences to the public domain. |
The Motley Fool
November 17, 2006
Jack Uldrich |
Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
BusinessWeek
November 6, 2006
Gene G. Marcial |
Solexa's Progress Is In The Genes New technology makes Solexa a leading contender in the next-generation sequencing race. |
Bio-IT World
November 2005 |
News Blast Applied Biosystems contributes 400,000 primers... Researchers have discovered the full genetic sequence of many different strains of the flu... Sigma-Aldrich launches Panorama Human Cancer Version 1 Protein Functional Microarray... |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
Bio-IT World
February 2006
Kevin Davies |
Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument. |
Pharmaceutical Executive
May 1, 2007 |
Deals: Roche Goes Shopping BioVeris purchase locks in a key diagnostic technology... Eisai buys Morphotek... IMS gets more outcomes-research muscle... etc. |
Bio-IT World
January 13, 2003
Julia Boguslavsky |
A Sequel to the Sequence The all-but-complete human genome sequence is not only an indispensable tool for biomedical research but also a major influence on the types of instrumentation researchers will invest in. |
BusinessWeek
October 23, 2008
John Carey |
Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon. |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
Bio-IT World
November 19, 2004
John Russell |
GSAC Rolls On Genome Sequencing and Analysis Conference rolls on... Stephen Quake discusses research on single-molecule DNA sequencing by synthesis... A photocleavable fluorescent nucleotide for DNA sequencing and analysis... |
IEEE Spectrum
February 2010
Mark Anderson |
Genome as Commodity In a few years, millions will have purchased their own genome. The cultural ramifications of a $100 genome are as wide and deep as those of any other recent innovation, including search engines and cellphones. |
Bio-IT World
July 2005 |
News Blast Applied Allied... Third Phase... Broad Broadens... In the Pipeline... |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
Bio-IT World
October 2006
Michael A. Greeley |
What Use Is the $1,000 Genome? Industry is focused on the $1,000 genome -- but investors want to see revenue and profits. The goal of simply reaching the $1,000 genome threshold inherently lacks a business model. What are the applications or products or services that will be unleashed by reaching that milestone? |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
August 19, 2011
Alexander Crawford |
DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list? |
Bio-IT World
December 10, 2002 |
Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The One Percent Difference New research reveals a shocking new layer of human genome variation with profound implications for the future of genomic analysis and personalized medicine. |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases. |
Chemistry World
January 28, 2015
Rebecca Trager |
Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Chemistry World
July 21, 2011
James Mitchell Crow |
Sequencing Chip Decodes DNA Proton by Proton Technology that can directly detect the chemical reaction as a single nucleotide adds to the end of a growing strand of DNA is about to slash the cost of genome sequencing, its inventors say. |
Bio-IT World
January 21, 2005
Kevin Davies |
A Vision for iScience Applied Biosystems president Catherine Burzik discusses integrated science, lab technology, and running a $2B business. |
Chemistry World
April 25, 2006
Jon Evans |
DNA Sequencing Reaches the Space Age The smallest ever DNA sequencer, only 10cm in diameter, comprises a complex network of microscopic pumps, valves, heaters and electrophoresis channels, many of which were initially developed for use in a device to detect life on Mars. |
